[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0202508A2 - Eljárás amiloid protein aggregáció gátlására és amiloid lerakódások kimutatására - Google Patents

Eljárás amiloid protein aggregáció gátlására és amiloid lerakódások kimutatására

Info

Publication number
HUP0202508A2
HUP0202508A2 HU0202508A HUP0202508A HUP0202508A2 HU P0202508 A2 HUP0202508 A2 HU P0202508A2 HU 0202508 A HU0202508 A HU 0202508A HU P0202508 A HUP0202508 A HU P0202508A HU P0202508 A2 HUP0202508 A2 HU P0202508A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
atom
protein aggregation
phenyl
Prior art date
Application number
HU0202508A
Other languages
English (en)
Inventor
Corinne Elizabeth Augelliszafran
Mark Robert Barvian
Christopher Franklin Bigge
Shelly Ann Glase
Shunichiro Hachiya
John Steven Keily
Takenori Kimura
Yingjie Lai
Annette Theresa Sakkab
Mark James Suto
Lary Craswell Walker
Tomoyuki Yasunaga
Nian Zhuang
Original Assignee
Warner-Lambert Company
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, Yamanouchi Pharmaceutical Co., Ltd. filed Critical Warner-Lambert Company
Publication of HUP0202508A2 publication Critical patent/HUP0202508A2/hu
Publication of HUP0202508A3 publication Critical patent/HUP0202508A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

A találmány amiloid protein aggregáció gátlására és amiloidlerakódások kimutatására szolgáló eljárásokra, az eljárásokbanalkalmazható (I) általános képletű vegyületek - amelyeknek képletébenRa jelentése hidrogénatom, 1-6 szénatomos alkilcsoport vagy (1-6szénatomos alkil)-karbonil-csoport; n értéke 0, 1, 2, 3, 4 vagy 5; R1,R2, R3, R4, R5, R6 és R7 jelentése egymástól függetlenül hidrogén-,halogénatom, hidroxi-, aminocsoport, -NRbRc általános képletű csoport,karboxicsoport, (1-6 szénatomos alkoxi)-karbonil-csoport,nitrocsoport, 1-12 szénatomos alkoxicsoport, 1-8 szénatomosalkilcsoport, trifluor-metil-, ciano-, adott esetben szubsztituáltbenzil-oxi-csoport, fenil-(CH2)m- általános képletű csoport, adottesetben szubsztituált fenoxicsoport, sztirilcsoport, -O(CH2)p-NRbRc, -CONRbRc, -NHCORb, -NH(CH2)pNRbRc, -N(1-6 szénatomos alkil) (CH2)pNRbRcáltalános képletű csoport vagy 1,3-bisz(1-6 szénatomos alkoxi)-2-propil-csoport; R8 jelentése karboxi-, tetrazolilcsoport, -SO2Rd vagy-CONH-SO2Rd általános képletű csoport; Rb és Rc jelentése egymástólfüggetlenül hidrogénatom, 1-6 szénatomos alkilcsoport, fenil-(CH2)m-általános képletű csoport, vagy Rb és Rc azzal a nitrogénatommalegyütt, amelyhez a két szubsztituens kapcsolódik, egy ciklusospiperidil-, pirrolil-, imidazolil-, piperazinil-, 4-(1-6 szénatomosalkil)-piperazinil-, morfolino-, tiomorfolino-,dekahidroizokinolilvagy pirazolilcsoportot képez; Rd jelentésehidrogénatom, 1-6 szénatomos alkilcsoport, trifluor-metil- vagyfenilcsoport; m értéke 0, 1, 2, 3, 4 vagy 5; p értéke 1, 2, 3, 4 vagy5; A jelentése metincsoport vagy nitrogénatom; valamint R1 és R2metilén-dioxi-csoportot is jelenthet, ha a két szubsztituens egymássalszomszédos helyzetben van < és gyógyászatilag elfogadható sóikra,valamint a vegyületeket tartalmazó gyógyszerkészítményekre vonatkozik.A találmány szerinti, az amiloid protein aggregáció gátlására szolgálóeljárást az Alzheimer-kór kezelésére alkalmazzák. Ó
HU0202508A 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits HUP0202508A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13855099P 1999-06-10 1999-06-10
PCT/US2000/015071 WO2000076489A2 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits

Publications (2)

Publication Number Publication Date
HUP0202508A2 true HUP0202508A2 (hu) 2002-12-28
HUP0202508A3 HUP0202508A3 (en) 2003-03-28

Family

ID=22482537

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202508A HUP0202508A3 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits

Country Status (30)

Country Link
EP (1) EP1225886A2 (hu)
JP (1) JP2003504310A (hu)
KR (1) KR20020008224A (hu)
CN (1) CN1378446A (hu)
AP (1) AP2002002387A0 (hu)
AU (1) AU775157B2 (hu)
BG (1) BG106293A (hu)
BR (1) BR0011728A (hu)
CA (1) CA2375551A1 (hu)
CR (1) CR6528A (hu)
DZ (1) DZ3252A1 (hu)
EA (1) EA004632B1 (hu)
EE (1) EE200100673A (hu)
GE (1) GEP20053423B (hu)
HK (1) HK1048258A1 (hu)
HR (1) HRP20020026A2 (hu)
HU (1) HUP0202508A3 (hu)
IL (1) IL146971A0 (hu)
IS (1) IS6193A (hu)
MA (1) MA26805A1 (hu)
MX (1) MXPA01012318A (hu)
NO (1) NO20015995L (hu)
NZ (1) NZ515621A (hu)
OA (1) OA11963A (hu)
PL (1) PL352430A1 (hu)
SK (1) SK17632001A3 (hu)
TR (1) TR200103551T2 (hu)
WO (1) WO2000076489A2 (hu)
YU (1) YU86701A (hu)
ZA (1) ZA200109794B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138374A1 (en) * 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
ES2327372B1 (es) * 2007-04-23 2010-08-24 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
US20080253967A1 (en) * 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2320897B1 (en) * 2008-08-29 2014-01-15 Treventis Corporation Compositions and methods of treating amyloid disease
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
WO2011101787A1 (en) * 2010-02-16 2011-08-25 Università Degli Studi Di Siena Non peptidic 14-3-3 inhibitors and the use thereof
JP2014504280A (ja) * 2010-11-24 2014-02-20 アラーガン インコーポレイテッド Ｓ１ｐ受容体調節剤
WO2018157842A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
KR20200042906A (ko) * 2017-08-07 2020-04-24 고쿠리츠다이가쿠호진 히로시마다이가쿠 신규 안트라닐산계 화합물, 및 이것을 사용한 Pin1 저해제, 염증성 질환의 치료제 및 암의 치료제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5739169A (en) * 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
ES2223531T3 (es) * 1999-06-10 2005-03-01 Warner-Lambert Company Llc Metodo de inhibir la agregacion de proteinas amiloides y de formacion de imagenes de depositos amiloides usando derivados de isoindolina.

Also Published As

Publication number Publication date
SK17632001A3 (sk) 2003-03-04
AU775157B2 (en) 2004-07-22
DZ3252A1 (hu) 2000-12-21
PL352430A1 (en) 2003-08-25
ZA200109794B (en) 2003-07-01
MA26805A1 (fr) 2004-12-20
HRP20020026A2 (en) 2003-08-31
AP2002002387A0 (en) 2002-03-31
CN1378446A (zh) 2002-11-06
AU5455300A (en) 2001-01-02
GEP20053423B (en) 2005-01-25
EE200100673A (et) 2003-02-17
EP1225886A2 (en) 2002-07-31
BR0011728A (pt) 2002-02-26
BG106293A (en) 2002-06-28
IL146971A0 (en) 2002-08-14
HUP0202508A3 (en) 2003-03-28
EA004632B1 (ru) 2004-06-24
YU86701A (sh) 2004-09-03
NO20015995D0 (no) 2001-12-07
MXPA01012318A (es) 2002-07-22
OA11963A (en) 2006-04-17
TR200103551T2 (tr) 2002-12-23
JP2003504310A (ja) 2003-02-04
WO2000076489A2 (en) 2000-12-21
CA2375551A1 (en) 2000-12-21
IS6193A (is) 2001-12-07
WO2000076489A3 (en) 2002-05-30
KR20020008224A (ko) 2002-01-29
CR6528A (es) 2004-02-23
NO20015995L (no) 2002-02-04
HK1048258A1 (zh) 2003-03-28
NZ515621A (en) 2004-05-28
EA200101135A1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
HUP0202508A2 (hu) Eljárás amiloid protein aggregáció gátlására és amiloid lerakódások kimutatására
HUP0300318A2 (hu) Pirazolobenzodiazepin-származékok, mint CDK2 inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0500173A2 (hu) Alfa-szulfonamido-acetamid-származékok mint béta-amiloid inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0301857A2 (hu) 3(5)-Ureido-pirazol-származékok, eljárás elżállításukra alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0301249A2 (hu) APO B termelődés gátló benzamid-vegyületek ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1108019T1 (el) Ενωσεις πυριμιδινης
HUP0301195A2 (hu) Alfa-4 integrin antagonista hatású aza-hidas biciklusos aminosav-származékok és ilyen vegyületeket tartalmazó gyógyszerkészítmények
HUP0201935A2 (hu) A SYK tirozin-protein-kináz inhibitoraiként alkalmazható purinszármazékok
HUP9904693A2 (hu) 26S és 20S Proteasome gátló hatású indanonszármazékok
CY1107108T1 (el) Παραγωγα αρυλομεθυλο-καρβονυλαμινο-θειαζολης και χρησις των ως αντινεοπλασματικοι παραγοντες
HUP9701193A2 (hu) N-(4-Aril-tiazol-2-il)-szulfonamid-származékok alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására, új származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0301493A2 (hu) Indolszármazékok, eljárás előállításukra és alkalmazásuk
HUP0105113A2 (hu) Benzoheterociklusos vegyületek és MEK inhibitorokként történő alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények
HUP0100615A2 (hu) Szubsztituált 2-(2,6-dioxo-3-fluoro-piperidin-3-il)-izoindolinok és ezek alkalmazása TNFalfa-szint csökkentésére
HUP0400828A2 (hu) Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0203448A2 (hu) Monoamin újrafelvétel inhibitorként alkalmazható új biaril-éter származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0401730A2 (hu) Új peptidek mint hepatitis C vírus NS3-szerin-proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
CA2373093A1 (en) Methods and compounds for inhibiting amyloid deposits
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
HUP9902148A2 (hu) Új 2,3-diszubsztituált-4(3H)-kinazolinonok
SE0104341D0 (sv) New use
SE9702799D0 (sv) New compounds
HUP0303272A2 (hu) Metabolikus modulátorként alkalmazható melonil-CoA dekarboxiláz inhibitor azol-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees